Trinity Biotech (TRIB) Projected to Post Earnings on Friday

Trinity Biotech (NASDAQ:TRIB) will likely be issuing its Q1 2025 results before the market opens on Friday, November 21st. Analysts expect the company to announce earnings of ($1.48) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 27, 2025 at 7:30 AM ET.

Trinity Biotech Stock Performance

Shares of TRIB stock opened at $0.84 on Thursday. Trinity Biotech has a fifty-two week low of $0.48 and a fifty-two week high of $3.44. The company has a 50 day moving average price of $1.03 and a 200 day moving average price of $2.82. The stock has a market capitalization of $3.03 million and a P/E ratio of -0.06.

Wall Street Analysts Forecast Growth

TRIB has been the topic of a number of recent research reports. Zacks Research raised Trinity Biotech to a “hold” rating in a research report on Monday, August 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Trinity Biotech in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Trinity Biotech stock. Perceptive Advisors LLC purchased a new position in shares of Trinity Biotech PLC (NASDAQ:TRIB) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,790,000 shares of the company’s stock, valued at approximately $1,164,000. Perceptive Advisors LLC owned 9.92% of Trinity Biotech at the end of the most recent reporting period. 78.97% of the stock is currently owned by institutional investors and hedge funds.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.